Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 2 |
2018 | 2 |
2019 | 3 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
J Nucl Med. 2016 Oct;57(Suppl 3):97S-104S. doi: 10.2967/jnumed.115.170167.
J Nucl Med. 2016.
PMID: 27694180
Free article.
Review.
177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney.
Zhang J, Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Langbein T, Baum RP.
Zhang J, et al. Among authors: niepsch k.
J Nucl Med. 2019 Nov;60(11):1579-1586. doi: 10.2967/jnumed.118.223149. Epub 2019 Mar 8.
J Nucl Med. 2019.
PMID: 30850499
Free article.
Item in Clipboard
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP.
Zhang J, et al. Among authors: niepsch k.
J Nucl Med. 2019 Mar;60(3):377-385. doi: 10.2967/jnumed.118.215848. Epub 2018 Aug 16.
J Nucl Med. 2019.
PMID: 30115686
Free article.
Item in Clipboard
Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy.
Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP.
Barber TW, et al. Among authors: niepsch k.
J Nucl Med. 2019 Jul;60(7):955-962. doi: 10.2967/jnumed.118.216820. Epub 2019 Jan 25.
J Nucl Med. 2019.
PMID: 30683770
Free article.
Item in Clipboard
[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, van Echteld CJ.
Baum RP, et al. Among authors: niepsch k.
Theranostics. 2016 Feb 13;6(4):501-10. doi: 10.7150/thno.13702. eCollection 2016.
Theranostics. 2016.
PMID: 26941843
Free PMC article.
Clinical Trial.
Item in Clipboard
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms.
Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Hörsch D.
Baum RP, et al. Among authors: niepsch k.
Oncotarget. 2018 Feb 15;9(24):16932-16950. doi: 10.18632/oncotarget.24524. eCollection 2018 Mar 30.
Oncotarget. 2018.
PMID: 29682195
Free PMC article.
Item in Clipboard
Cite
Cite